The US Patent Trial and Appeal Board (PTAB) has denied the St Regis Mohawk Tribe's motion to terminate Mylan's (Nasdaq: MYL) patent challenge regarding six patents related to Allergan's (NYSE: AGN) dry-eye drug Restasis (cyclosporine).
Allergan announced last September that it had assigned the rights of six patents to the tribe, hoping that since it was a sovereign government, usual patent-office review would not apply.
"The ruling reinforces our belief that Allergan's maneuvers to engage the St Regis Mohawk Tribe for patent protection were a sham"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze